Clinical trial
A Study on the Safety, Preliminary Efficacy, and Cellular Kinetics of Allogeneic CD7-Targeted CAR-T Cell Injection for the Treatment of Type 1 Diabetes Mellitus
NCT07528105 is registered in ClinicalTrials.gov with Shanghai Zhongshan Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Study on the Safety, Preliminary Efficacy, and Cellular Kinetics of Allogeneic CD7-Targeted CAR-T Cell Injection for the Treatment of Type 1 Diabetes Mellitus
- Lead sponsor
- Shanghai Zhongshan Hospital
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- April 30, 2026
- Completion date
- April 30, 2028
- Enrollment
- 9 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
t1dm - type 1 diabetes mellitus